VBI VACCINES INC. (TSE:VBV) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officer.
As previously reported, on October 18, 2018, Steven D. Rubin and Adam Logal tendered their resignations from the Board of Directors (the “Board”) and all Board committees of VBI Vaccines Inc. (the “Company”), effective October 18, 2018.
On January 11, 2019, Blaine McKee was appointed to the Board, effective as of January 11, 2019, to fill one of the vacancies on the Board created by the resignation of Mr. Rubin and Mr. Logal, to serve for a term expiring at the next annual meeting of stockholders or until his successor is duly elected and qualified.
Item 8.01 Other Events.
On January 16, 2019, the Company issued a press release announcing the appointment of Mr. McKee. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
|99.1||Press Release dated January 16, 2019|
VBI Vaccines Inc/BC Exhibit
EX-99.1 2 ex99-1.htm VBI Vaccines Appoints Blaine McKee to Board of Directors CAMBRIDGE,…
To view the full exhibit click
About VBI VACCINES INC. (TSE:VBV)
VBI Vaccines Inc. is a development-stage biotechnology company. The Company’s principal products include cytomegalovirus (CMV) Vaccine Candidate, enveloped Virus Like Particle (eVLP) Vaccine Platform and Lipid Particle Vaccine (LPV) Vaccine Platform. The Company is also engaged in the research and development (R and D) activity. The Company’s subsidiaries includes Variation Biotechnologies (US), Inc. (VBI US) and Variation Biotechnologies Inc. (VBI Cda).